{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["67(2)"],"submitter":["Fisher TS"],"pubmed_abstract":["Strong evidence exists supporting the important role T cells play in the immune response against tumors. Still, the ability to initiate tumor-specific immune responses remains a challenge. Recent clinical trials suggest that bispecific antibody-mediated retargeted T cells are a promising therapeutic approach to eliminate hematopoietic tumors. However, this approach has not been validated in solid tumors. PF-06671008 is a dual-affinity retargeting (DART<sup>®</sup>)-bispecific protein engineered with enhanced pharmacokinetic properties to extend in vivo half-life, and designed to engage and activate endogenous polyclonal T cell populations via the CD3 complex in the presence of solid tumors expressing P-cadherin. This bispecific molecule elicited potent P-cadherin expression-dependent cytot"],"journal":["Cancer immunology, immunotherapy : CII"],"pagination":["247-259"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028296"],"repository":["biostudies-literature"],"pubmed_title":["A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice."],"pmcid":["PMC11028296"],"pubmed_authors":["Haddish-Berhane N","May C","Fisher TS","Golas J","Elliott MW","Hooper AT","Wang H","Clark TH","Gavriil M","Tchistiakova L","Rohner AK","Root AR","Lucas J","Tsaparikos K","Peano B","Gerber HP"],"additional_accession":[]},"is_claimable":false,"name":"A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.","description":"Strong evidence exists supporting the important role T cells play in the immune response against tumors. Still, the ability to initiate tumor-specific immune responses remains a challenge. Recent clinical trials suggest that bispecific antibody-mediated retargeted T cells are a promising therapeutic approach to eliminate hematopoietic tumors. However, this approach has not been validated in solid tumors. PF-06671008 is a dual-affinity retargeting (DART<sup>®</sup>)-bispecific protein engineered with enhanced pharmacokinetic properties to extend in vivo half-life, and designed to engage and activate endogenous polyclonal T cell populations via the CD3 complex in the presence of solid tumors expressing P-cadherin. This bispecific molecule elicited potent P-cadherin expression-dependent cytot","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Feb","modification":"2025-04-22T20:42:24.266Z","creation":"2025-04-06T03:17:16.459Z"},"accession":"S-EPMC11028296","cross_references":{"pubmed":["29067496"],"doi":["10.1007/s00262-017-2081-0"]}}